Trial Profile
A Phase II Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study to Determine the Efficacy and Dose Response of Repeat Inhaled Doses of GW870086X on FEV1 in Adults With Persistent Asthma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Sep 2023
Price :
$35
*
At a glance
- Drugs GSK 870086 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GSK
- 05 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 May 2011 Actual initiation date (December 2010) added as reported by ClinicalTrials.gov.
- 20 May 2011 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.